Compare CarMax, Inc (KMX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? CarMax, Inc trades at $52.02 (market cap $7.07B), while Travere Therapeutics Inc. Common Stock trades at $54.62 (market cap $5.02B). The key difference: CarMax, Inc is the larger of the two by market cap, and CarMax, Inc is more actively traded (2,330,911.51 versus 2,060,842). Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KMX | TVTX | |
|---|---|---|
Market Cap | $7.07B | $5.02B |
Volume | 2,330,911.51 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $67.52 |
52-Week Low | $30.88 | $26.79 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $24.77B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $50.81, up 0.24% with bearish technical signals despite recent earnings beats. The company reported strong Q2 2027 results with EPS of $1.16 beating estimates by 58%, driven by 19.5% revenue growth to $7.9 billion. However, net income margin remains thin at 1.06% and cash flow trends show recent weakness with negative net cash flow of $290 million in 2025.
While CarMax's turnaround strategy shows early success with improved sales volume, high debt levels and compressed margins present significant risks. The consensus price target of $61 offers 20% upside potential, but technical indicators suggest near-term pressure. The stock faces headwinds from competitive pricing pressures and macroeconomic sensitivity to consumer spending.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
